Dr. Donna Kimbark discusses CDMRP’s unique non-dilutive funding opportunities for cancer R&D.
Dr. Akua Roach discusses non-dilutive funding opportunities through CDMRP.
Dr. William Bozza discusses non-dilutive funding opportunities at NCI and NIH.
Dr. Charles L. Cywin discusses non-dilutive funding opportunities at NINDS and NIH.
Dr. Daniel Gossett discusses non-dilutive funding opportunities at NIDDK and NIH.
Dr. Abla Creasey discusses non-dilutive funding opportunities at the California Institute for Regenerative Medicine, which funds stem cell R&D.
Dr. Natalia Kruchinin discusses non-dilutive funding opportunities at NIAID and NIH.
Nick Damiano, co-founder and CEO of Abalone Bio, discusses the company’s success with non-dilutive funding. Abalone Bio is the first company to win funding from FreeMind Investments.
Nick Damiano, co-founder and CEO of Zenflow, discusses the company’s success with non-dilutive funding.
Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix, discusses the company’s success with non-dilutive funding.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109